NASDAQ$MREO

Mereo Biopha-Adr · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

MREO Q1 2023 — extraction skipped

Mereo Biopha-Adr filed Form 6-K (accession 0001193125-23-082243) for Q1 2023, but headline financial numerics could not be extracted automatically: no headline numerics found by parser nor by Financial Datasets fallback. The row is marked as AI-processed so the queue advances; numerics will be filled by Financial Datasets on its next pass.

  • Form 6-K filed; press release body not parseable here.
  • Reason: no headline numerics found by parser nor by Financial Datasets fallback.
  • Numerics rely on the Financial Datasets fallback.

Headline financials

EPS (adj)

-$0.02

No prior period
Net Income

-$12.1M

No prior period
Operating Income

-$11.4M

No prior period
Stock-Based Comp

$1.64M

No prior period

Revenue & EPS history

Mereo Biopha-Adr · Revenue · Quarterly

$0

Q3 2025
Beat estimate in 0 of 4 quarters(0%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+3.4%

Avg return

Earnings day

+0.4%

Avg return

5 days after

+17.3%

Avg return

30 days after

69%

9 / 13 earnings

Positive

+11.9%

Q4 2023

Best reaction

-6.1%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+4.1%+0.9%
Q4 2025+4.6%-4.5%-4.3%
Q3 2025+6.3%+0.6%+27.1%
Q2 2025+9.4%+14.5%+19.7%
Q1 2025+1.3%-2.2%+25.3%
Q4 2024-3.6%-11.6%+15.6%
Q3 2023-5.4%-17.5%-12.9%
Q3 2024-5.4%-17.5%-12.9%
Q2 2024+6.2%+16.4%+18.0%
Q1 2023+10.5%+10.1%+43.6%
Q1 2024+10.5%+10.1%+43.6%
Q4 2023+11.9%+15.6%-7.1%
Q4 2022-6.1%-10.3%+52.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro